Intersect ENT Inc

Intersect ENT — Investor Presentation (May 2015)

26 slides from Intersect ENT's investor presentation, May 11, 2015

  1. Slide 1: Company Presentation May 2015

    MAY 2015 Company Presentation Exhibit 99.1

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements Certain statements in this presentation constitute “forward-looking statements” within the meaning of the Securities Act of 1933, as amended (the “Securities Act”), and Securities Exchange Act of 1934, as amended (“Exchange Act”), including, without limitation, statements

  3. Slide 3: Advancing Clinically-Proven Therapies for Ear, Nose and Throat

    ADVANCING CLINICALLY-PROVEN THERAPIES for Ear, Nose and Throat (ENT) Physicians and Patients Focus on Chronic Sinusitis (CS) 29M Patients in US IMPROVING QUALITY OF LIFE from Surgery to Office Care

  4. Slide 4: Chronic Sinusitis: Significant Unmet Need

    Chronic Sinusitis: Significant Unmet Need DEBILITATING INFLAMMATORY CONDITION in Adults 3.5M Managed by ENT 500,000+ Surgeries / Year Top 10 Most Costly Condition for US Employers

  5. Slide 5: Improving Surgical Outcomes

    IMPROVING SURGICAL OUTCOMES 1st Two Commercial Products st Drug Releasing Implants for Chronic Sinusitis Patients Only PMA Approval for CS Patients 60,000+ Patients to Date Reduced Inflammation, Scarring and Need for Additional Surgery and Oral Steroids

  6. Slide 6: Large Market, Unique Products, Product Pipeline, Track Record

    LARGE MARKET UNIQUE PRODUCTS PRODUCT PIPELINE TRACK RECORD Intersect ENT Opportunity $4.8B TAM in US st and Only Drug Releasing Implants in ENT In-Office Products to Serve Continuum of Care Strong Revenue Growth and Gross Margins (70+%) ANNUAL REVENUE ($M) $6 $18 $39

  7. Slide 7: Challenges Across the Continuum of Care

    Challenges Across the Continuum of Care CS Treatment Pathway Oral Steroids Reduce Inflammation but Can Cause Side Effects MEDICATION TO TREAT Surgery Opens Pathways but Can Result in Post-Operative Scarring and Inflammation SURGERY TO OPEN (FESS) Within One Year, 64% Symptom Recurrence and 10% Revis

  8. Slide 8: Our Solution Portfolio

    Our Solution Portfolio MEDICATION TO TREAT SURGERY TO OPEN MANAGEMENT TO MAINTAIN NOVA RESOLVE PROPEL Office Treatment for Primary CS Patients Office Treatment for Recurrent CS Patients Treatment to Improve Surgical Outcomes NOVA and RESOLVE are investigational and not currently available for sale i

  9. Slide 9: PROPEL / PROPEL Mini: How It Works

    ETHMOID SINUS PROPEL / PROPEL MINI How It Works OPENS Self-expanding Implant Conforms to and Holds Open Sinus DELIVERS Sustained, Targeted Delivery of Steroid Over 30 Days MAINTAINS Opening by Reducing Post-operative Inflammation and Scarring Advanced into Surgically Enlarged Sinus Cavity

  10. Slide 10: Reduction in Post-Operative Medical and Surgical Interventions

    Reduction in Post-Operative Medical and Surgical Interventions PROPEL Clinically Proven Surgical Outcomes Meta-analysis: Han JK, Marple BF, Smith TL et al. Int Forum Allergy Rhinol, Vol. 2, No. 4, July/August 2012 • 3 Prospective Trials, 200+ Patients • Only Device Used in Sinus Surgery Backed by Le

  11. Slide 11: Early in Adoption Cycle

    Early in Adoption Cycle in Accounts in Sinus Surgeons in Patients PENETRATION* Early in Adoption Cycle PROPEL Commercial Success REIMBURSEMENT • FESS ~$14K • Propel Treated as Surgical Supply • ASP $728 REVENUE ($M) SALESFORCE • US Only • 66 Territory Managers • 10,000 ENTs • 7,500 Perform FESS 78%

  12. Slide 12: Strong Base to Drive Forward Revenue

    Strong Base to Drive Forward Revenue CONSISTENT ANNUALIZED SALES/TERRITORY MGR ($000) GROWING BASE OF RECURRING REVENUE ($M) Ending # of TMs Annualized Sales/TM New Reorder 85% PROPEL $- $200 $400 $600 $800 $1,000 $1,200 Q1/14 Q2/14 Q3/14 Q4/14 Q1/15 $0 $2 $4 $6 $8 $10 $12 $14 $16 Q1/14 Q2/14 Q3/14

  13. Slide 13: Frontal Sinus Investigational Progress

    FRONTAL SINUS INVESTIGATIONAL PROGRESS GOAL Demonstrate Reduction in Need for Post-Operative Interventions Such as Additional Surgery and Oral Steroids PROPEL MINI Expanding Indications Seeking Expanded Indication for Placement in Frontal Sinus 25% of Sinus Surgeries Currently Enrolling Prospective,

  14. Slide 14: Our Solution Portfolio: In-Office Therapies

    NOVA RESOLVE PROPEL Office Treatment for Primary CS Patients Office Treatment for Recurrent CS Patients Treatment to Improve Surgical Outcomes MEDICATION TO TREAT MANAGEMENT TO MAINTAIN Our Solution Portfolio: In-Office Therapies SURGERY TO OPEN NOVA and RESOLVE are investigational and not currently

  15. Slide 15: RESOLVE: How It Works

    ETHMOID SINUS RESOLVE How It Works Investigational Drug Only. Not approved for sale in U.S. • For Patients with Refractory CS/Polyps • To Dilate Obstructed Cavity • To Deliver Steroid Over 90 Days • Less Invasive, More Cost Effective vs. Revision Surgery IN-OFFICE POST PRIOR SURGICAL TREATMENT Ethmo

  16. Slide 16: Reduction in Polyp Burden and Patient Symptoms

    Reduction in Polyp Burden and Patient Symptoms RESOLVE Promising Results Change from Baseline in Endoscopic and Symptom Scores vs. Sham Procedure. Format modified from Han JK, Forwith KD, Smith TL, et al. RESOLVE: a randomized, controlled, blinded study of bioabsorbabl e steroid releasing sinus impl

  17. Slide 17: RESOLVE IND Clinical Program

    STUDY DESCRIPTION N SITES PUBLISHED RESOLVE IND Clinical Program STUDY DESCRIPTION N SITES PUBLISHED PILOT Non-Randomized Open Label Single Cohort PHARMACOKINETIC (PK) Non-Randomized Open Label Single Cohort RESOLVE Phase II / III Randomized 1:1 Blinded Implants vs. Sham Procedure RESOLVE II Phase I

  18. Slide 18: NOVA: How It Works

    FRONTAL AND MAXILLARY SINUSES NOVA How It Works Investigational Device Only. Not approved for sale in U.S. • Primary (Including Post Dilation) or Revision Patients • Hourglass Shape to Maximize Tissue Apposition and Support • Regulatory Pathway: PMA-S • Feasibility Study Completed (15 Patients, 2 US

  19. Slide 19: Large U.S. Market Opportunity

    $830M $1.1B $2.8B SURGICAL PROPEL 540K Patients Large U.S. Market Opportunity $4.8B in US NOVA PRIMARY 2.3M Patients RESOLVE REFRACTORY 770K Patients

  20. Slide 20: Emerging Opportunity Outside the US

    Emerging Opportunity Outside the US ~540K FESS / Year ~450K FESS / Year ~250K FESS / Year ATTRACTIVE MARKET OPPORTUNITIES DEVELOPING MARKET COMMERCIALIZATION PLANS Targeting 4-6 Large Markets in Europe and Asia Pacific Regulatory Pathways (Especially China, Japan) Reimbursement Activities Market Ent

  21. Slide 21: Industry Landscape

    STEROIDS SURGICAL TOOLS / SUPPLIES Industry Landscape We Are a Unique Solution – Complementary to Other Technologies MEDICATION TO TREAT SURGERY TO OPEN MANAGEMENT TO MAINTAIN

  22. Slide 22: Multiple Barriers to Entry

    • • • Multiple Barriers to Entry REGULATORY Only Drug Releasing Implants in ENT Two PMA Approvals RESOLVE: NDA Pathway R&D / MANUFACTURING • 50,000 ft Facility in Menlo Park, CA • Specialized Capabilities in Bioabsorbable DES • Robust Quality System INTELLECTUAL PROPERTY • 55 Issued Patents (29 US /

  23. Slide 23: Outlook: Milestones

    Outlook: Milestones GROWTH LEVERS NOVA RESOLVE PROPEL PROGRESS Frontal Indication Enrollment Complete Frontal Indication PROPEL mini PMA-S Approval RESOLVE II Enrollment Complete NDA Approval PMA-S Approval maxillary Clinical Trials RESOLVE II Enrollment Commenced Commercial Clinical International O

  24. Slide 24: Experienced Leadership

    Experienced Leadership MANAGEMENT TEAM LISA EARNHARDT President & CEO RICH KAUFMAN COO, SVP R&D & Operations JERI HILLEMAN CFO ROB BINNEY VP Sales SUSAN STIMSON VP Marketing JAMES STAMBAUGH VP Clinical Affairs AMY WOLBECK VP Regulatory Affairs & Quality CHAS McKHANN Chief Commercial Officer EXPERIEN

  25. Slide 25: $4.8B US Market

    $4.8B US Market and ONLY Drug Releasing Implants in ENT EMERGING In - Office Portfolio TRACK RECORD Strong Revenue Growth & GMs st

  26. Slide 26: Intersect ENT

    intersect’ ENT

Intersect ENT — Investor Presentation (May 2015) on 6ix